What this study is
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
What's being tested
- Sirolimus
Intervention · DRUG
Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
- Everolimus
Intervention · DRUG
Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Study details
- Official title
- Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)
- Sponsor
- University of Cincinnati
- Conditions
- Lymphangioleiomyomatosis
- Enrolling
- 600 people
- Starts
- 2015-03
- Est. completion
- 2025-07-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex FEMALEHealthy volunteers Not acceptedYou may qualify if
- Female or male, age 18 or over
- Diagnosis of LAM based on ATS/JRS criteria
- Signed and dated informed consent
- On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy
You can't join if
- Inability to attend at least one RLD Clinic visit per year
- Inability to give informed consent
- Inability or unwillingness to perform pulmonary function testing
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (20)
8 openStanford University Medical Center
Stanford, California, United States
- Stephen Ruoss, MD · Contact650-723-6381ruoss@stanford.edu
RecruitingNational Jewish Health
Denver, Colorado, United States
- Gregory Downey, MD · Contact303-398-1436 ext. 1881gregory.downey@gmail.com
RecruitingMayo Clinic Jacksonville
Jacksonville, Florida, United States
- Charles Burger, MD · Contact904-953-2381charles.burger@mayo.edu
RecruitingEmory University School of Medicine
Atlanta, Georgia, United States
- Sirhari Veeraraghavan, MD · Contactveeraraghavan@emory.edu
RecruitingBrigham and Women's Hospital
Boston, Massachusetts, United States
- Elizabeth Henske, MD · Contact857-307-0784ehenske@partners.org
RecruitingUniversity of Michigan
Ann Arbor, Michigan, United States
- Mei Lan Han, MD · Contact734-936-5047mrking@umich.edu
RecruitingWashington University School of Medicine
St Louis, Missouri, United States
- Adrian Shifren, MD · Contact314-362-6904ashifren@wustl.edu
RecruitingUniversity of Rochester Medical Center
Rochester, New York, United States
- MaryAnne Morgan, MD · Contact585-275-4161maryanne_morgan@urmc.rochester.edu
RecruitingLoyola University Medical Center, Chicago
Maywood, Illinois, United States
Active, not recruitingMayo Clinic Rochester
Rochester, Minnesota, United States
Active, not recruitingUniversity of Cincinnati
Cincinnati, Ohio, United States
Active, not recruitingCleveland Clinic
Cleveland, Ohio, United States
Active, not recruitingOregon Health and Science University
Portland, Oregon, United States
Active, not recruitingUniversity of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Active, not recruitingMedical University of South Carolina
Charleston, South Carolina, United States
Active, not recruitingVanderbilt University Medical Center
Nashville, Tennessee, United States
Active, not recruitingUniversity of Texas Southwestern Medical Center
Dallas, Texas, United States
Active, not recruitingUniversity of Texas Health Center
Houston, Texas, United States
Active, not recruitingUniversity of Utah School of Medicine
Salt Lake City, Utah, United States
Active, not recruitingSwedish Medical Center
Seattle, Washington, United States
Active, not recruiting
Study team
Sponsor
University of Cincinnati
Study ID MIDAS
Study director
Francis X McCormack, MD
University of Cincinnati
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.